Tvardi Therapeutics (TVRD) stock plummeted on Monday after the clinical-stage biopharmaceutical company announced results from its Phase 2 REVERT clinical trial of TTI-101. This was a trial to test the effectiveness of TTI-101 alone or in combination with nintedanib to treat patients with idiopathic pulmonary fibrosis (IPF). IPF is a progressive and fatal lung disease that causes irreversible scarring.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The bad news here is that early data from the trial showed no statistically significant differences between the placebo and treatment arms. Imran Alibhai, CEO of Tvardi Therapeutics, said the company will continue to evaluate the data to better decide what its next actions should be.
The Tvardi Therapeutics CEO also provided investors with insight into the company’s other candidates. He noted that the company remains “on track to report preliminary topline data in the first half of 2026 from a healthy volunteer study on our next-generation STAT3 inhibitor, TTI-109, and from the Phase 2 trial of TTI-101 in hepatocellular carcinoma.”
Tvardi Therapeutics Stock Movement Today
Tvardi Therapeutics stock plummeted 86.61% in pre-market trading on Monday, following a 3.21% fall on Friday. The shares were up 126.58% year-to-date and 351.24% over the past 12 months. Today’s news came with heavy trading as some 928,000 shares changed hands, compared to a three-month daily average of about 55,400 units.
Is Tvardi Therapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Tvardi Therapeutics is Strong Buy, based on five Buy ratings over the past three months. With that comes an average TVRD stock price target of $62.40, representing a potential 50% upside for the shares.
